Fresh off the release of new data in its multiple sclerosis program, Atara Biotherapeutics added $175 million to its coffers as it gears up to take its primary product to market. A clinical study of its MS therapy ATA188 released both promising safety data and early evidence that it could improve disability in patients. Just…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
